ADAR1-mediated RNA editing promotes B cell lymphomagenesis

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Diffuse large B cell lymphoma (DLBCL) is a prevalent aggressive lymphoid cancer.
• Understanding the molecular mechanisms driving DLBCL pathogenesis is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of RNA editing in the development of DLBCL.
• To explore the interplay between DNA mutations and RNA editing in DLBCL.
• To elucidate the functional consequences of RNA editing in key signaling pathways relevant to DLBCL.

Main Methods:

• Comparative analysis of DNA mutations and RNA editing events in DLBCL samples.
• Transcriptomic and proteomic profiling to assess RNA editing impacts.
• Functional studies using targeted RNA base editing tools in cell models.

Main Results:

• DNA mutations and RNA editing events were frequently mutually exclusive in DLBCL.
• RNA editing was observed in transcripts involved in apoptosis, p53, NF-κB, and RIG-I-like signaling pathways.
• ADAR1-mediated editing of the MAVS transcript correlated with increased MAVS protein, interferon/NF-κB signaling, and T cell exhaustion.
• Restoring MAVS 3'UTR editing in ADAR1-deficient cells increased downstream signaling.

Conclusions:

• RNA editing is a significant mechanism in DLBCL pathogenesis, offering an alternative to genomic alterations for modulating pathway outcomes.
• ADAR1-mediated RNA editing of MAVS contributes to immune signaling and T cell exhaustion in DLBCL.
• Targeted RNA editing interventions may hold therapeutic potential for DLBCL.